Susumu Kageyama1, Koki Maeda2,3, Shigehisa Kubota2, Tetsuya Yoshida2, Takashi Osafune4, Yutaka Arai5, Hiroki Soga6, Zenkai Nishikawa7, Yuji Sakano8, Keita Takimoto9, Chul Jang Kim10, Tokuhiro Chano11, Akihiro Kawauchi2. 1. Department of Urology, Shiga University of Medical Science, Shiga, Japan; kageyama@belle.shiga-med.ac.jp. 2. Department of Urology, Shiga University of Medical Science, Shiga, Japan. 3. Department of Urology, Nagahama Red Cross Hospital, Shiga, Japan. 4. Department of Urology, Uji-Tokushukai Medical Center, Kyoto, Japan. 5. Department of Urology, Kusatsu General Hospital, Shiga, Japan. 6. Department of Urology, Toyosato Hospital, Shiga, Japan. 7. Department of Urology, Hino Memorial Hospital, Shiga, Japan. 8. Department of Urology, Higashi-Ohmi General Medical Center, Shiga, Japan. 9. Department of Urology, Saiseikai Shiga Hospital, Shiga, Japan. 10. Department of Urology, Kohka Public Hospital, Shiga, Japan. 11. Department of Clinical Laboratory Medicine, Shiga University of Medical Science, Shiga, Japan.
Abstract
BACKGROUND: This study evaluated the efficacy of a single instillation of pirarubicin with a short retention time for preventing intravesical recurrence of low-risk non-muscle-invasive bladder cancer. PATIENTS AND METHODS: We analyzed 165 patients with low-risk non-muscle-invasive bladder cancer who underwent transurethral surgery. Single instillation of pirarubicin with 15-min retention time immediate after surgery was performed in 47 (28%) patients. The other patients (118, 72%) were treated without instillation therapy. The primary endpoint was recurrence-free survival. RESULTS: Median overall follow-up was 50 (range=6-134) months. Recurrence-free survival at 1 and 5 years was 91% and 72%, and 79% and 54% in the group treated with pirarubicin, and that treated with surgery alone, respectively (p=0.031). Cox's hazard analysis revealed lack of instillation and larger tumor size (>10 mm) as significant factors for risk of recurrence. No adverse events regarding intravesical chemotherapy were observed. CONCLUSION: Pirarubicin instillation with 15-min retention time can prevent intravesical recurrence of low-risk bladder tumors. Copyright
BACKGROUND: This study evaluated the efficacy of a single instillation of pirarubicin with a short retention time for preventing intravesical recurrence of low-risk non-muscle-invasive bladder cancer. PATIENTS AND METHODS: We analyzed 165 patients with low-risk non-muscle-invasive bladder cancer who underwent transurethral surgery. Single instillation of pirarubicin with 15-min retention time immediate after surgery was performed in 47 (28%) patients. The other patients (118, 72%) were treated without instillation therapy. The primary endpoint was recurrence-free survival. RESULTS: Median overall follow-up was 50 (range=6-134) months. Recurrence-free survival at 1 and 5 years was 91% and 72%, and 79% and 54% in the group treated with pirarubicin, and that treated with surgery alone, respectively (p=0.031). Cox's hazard analysis revealed lack of instillation and larger tumor size (>10 mm) as significant factors for risk of recurrence. No adverse events regarding intravesical chemotherapy were observed. CONCLUSION:Pirarubicin instillation with 15-min retention time can prevent intravesical recurrence of low-risk bladder tumors. Copyright
Authors: Andreas Böhle; Herbert Leyh; Christian Frei; Michael Kühn; Reinhold Tschada; Tobias Pottek; Walter Wagner; Helmut H Knispel; Wolfgang von Pokrzywnitzki; Ferruh Zorlu; Karin Helsberg; Birgit Lübben; Victoria Soldatenkova; Clemens Stoffregen; Hartwig Büttner Journal: Eur Urol Date: 2009-06-21 Impact factor: 20.096
Authors: Ashish M Kamat; Noah M Hahn; Jason A Efstathiou; Seth P Lerner; Per-Uno Malmström; Woonyoung Choi; Charles C Guo; Yair Lotan; Wassim Kassouf Journal: Lancet Date: 2016-06-23 Impact factor: 79.321
Authors: Sam S Chang; Stephen A Boorjian; Roger Chou; Peter E Clark; Siamak Daneshmand; Badrinath R Konety; Raj Pruthi; Diane Z Quale; Chad R Ritch; John D Seigne; Eila Curlee Skinner; Norm D Smith; James M McKiernan Journal: J Urol Date: 2016-06-16 Impact factor: 7.450